Life Sciences & Diagnostic Tools Analyst Massaro discusses Castle Biosciences’ (CSTL) TissueCypher Test–what, why and how much, on an Analyst/Industry conference call to be held on October 2 at 1 pm.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL:
- Castle Biosciences: DecisionDx -Melanoma can precise predict SLN positivity risk
- Castle Biosciences: New study shows DecisionDx-SCC test benefits SCC patients
- Castle Biosciences management to meet virtually with Lake Street
- Castle Biosciences price target raised to $37 from $34 at Baird
- Closing Bell Movers: Lumen surges after securing $5B in new business